Feature | February 17, 2014

UTHealth, Memorial Hermann Perform Conscious Sedation TAVR Procedure

TAVR Heart valve repair Hybrid OR
February 17, 2014 — A team of interventional cardiologists and cardiovascular surgeons at The University of Texas Health Science Center at Houston (UTHealth) and Memorial Hermann Heart & Vascular Institute-Texas Medical Center performed Texas’ first transcatheter aortic valve replacement (TAVR) under conscious sedation using the Edwards Sapien valve.
 
Conscious sedation, in which the patient is awake and able to communicate with physicians during the procedure, is now used in many TAVR cases in Europe but is much less common in the United States.
 
The procedure circumvents an anesthesiologist inserting a breathing tube for general anesthesia. Conscious sedation can mean less recovery time, a shorter hospital stay and cost savings, physicians have reported. For traditional surgical aortic valve replacements, the hospital length of stay is five to six days. By comparison, the length of stay for TAVRs in Europe can be as low as one to two days.
 
Aortic valve stenosis, which affects approximately 300,000 Americans, is an age-related disease resulting from calcium deposits in the valve that cause it to narrow and stiffen. As it becomes harder to pump the blood to the rest of the body, the heart weakens. Patients experience fainting, chest pain, heart failure, irregular heart rhythms and cardiac arrest. Without treatment, patients usually die within two years of diagnosis.
 
This first case in Texas on Jan. 9, 2014 went so well that when patient Clifford Reed’s wife Helen arrived at the hospital a day after her husband received his new aortic valve, he was dressed and ready to go home. His doctors elected to keep him one more day for monitoring.
 
“We're not removing a tooth or sewing up a wound under conscious sedation, but doing a procedure that in the past required stopping the heart, placing the patient on cardiopulmonary bypass, removing the aortic valve, and suturing a new valve into place,” said Tom C. Nguyen, M.D. assistant professor of cardiovascular surgery at the UTHealth Medical School and cardiothoracic and vascular surgeon at the Institute. “In essence, we're doing heart surgery while the patient is partially awake.”
 
Replacing the aortic valve is traditionally done in surgery in the United States, but some patients are not candidates for surgery. TAVR, which is done via a catheter inserted into an artery, has been studied in Europe and the United States for more than a decade in frail patients who are inoperable or at high risk for open surgery.
 
Doing the procedure under conscious sedation was a natural next step.
 
“As our population ages, more and more of us are going to have these kinds of conditions and the less invasively we can manage them, the better these patients will hopefully be in the future,” said Prakash Balan, M.D., assistant professor of interventional cardiology at the UTHealth Medical School and part of the Institute team performing the procedure.
 
“With this procedure, we were able to put in a new valve while the patient was awake in about an hour and 10 minutes, so that’s a huge advance,” said Richard W. Smalling, M.D., Ph.D., the James D. Woods Distinguished Chair in Cardiovascular Medicine and director of interventional cardiovascular medicine in the Division of Cardiology at UTHealth and the Institute.
 
As he was wheeled out of the catheter lab, Clifford Reed, who is 87, told Nguyen and Balan that he was “feeling a lot better now.”
 
His wife noticed an immediate change.
 
“Before he used to be light-headed and he wasn’t sure on his feet. He also had a lot of chest pain,” Helen Reed said. “Now his chest isn’t hurting and he’s doing great. It’s a miracle.”
 
For more information: www.uth.edu
 

Related Content

A CT scan assessment of the femoral access route challenges for a recent Central DuPage Hospital TAVR candidate. This image and the measurements were discussed by the heart team during its weekly meeting to determine if the TAVR delivery catheters could navigate the disease femoral artery and what options might best serve this patient.

A CT scan assessment of the femoral access route challenges for a recent Central DuPage Hospital TAVR candidate. This image and the measurements were discussed by the heart team during its weekly meeting to determine if the TAVR delivery catheters could navigate the disease femoral artery and what options might best serve this patient. 

 

Feature | Heart Valve Technology | April 20, 2018 | Dave Fornell
While there is fear by many about the trend of hospitals consolidating into larger healthcare systems, one advantage
A transcaval access TAVR procedure, showing a guide wire in the vena cava and a snare located in the aorta to pull the guide wire through.

A transcaval access TAVR procedure, showing a guide wire in the vena cava and a snare located in the aorta to pull the guide wire through.

Feature | Heart Valve Technology | April 19, 2018 | Dave Fornell
Patient selection for who is best suited for a ...
Videos | Heart Valve Technology | April 18, 2018
Northwestern Medicine has purchased several smaller Chicago suburban hospitals in the past few years to expand its he
University Hospitals Performs Ohio's First Transcatheter Mitral Valve Replacement
News | Heart Valve Technology | April 06, 2018
University Hospitals Harrington Heart & Vascular Institute has officially opened the APOLLO trial, implanting the...
LivaNova Announces Enrollment for PERFECT Perceval Valve Clinical Trial in China
News | Heart Valve Technology | March 30, 2018
LivaNova PLC announced the first patient enrollment in the Perceval Valve Clinical study for Chinese Registration (“...
Edwards Completes Enrollment in PARTNER 3 Low-Risk CT Sub-Study
News | Heart Valve Technology | March 27, 2018
March 27, 2018 — Edwards Lifesciences Corp.
Videos | Heart Valve Technology | March 15, 2018
Insights from the STS/ACC TVT Transcatheter Valve Registry, presented at the American College of Cardiology (ACC) 201
CoreValve TAVR System Shows Strong Long-Term Performance in Clinical Trials
News | Heart Valve Technology | March 12, 2018
Medtronic plc unveiled outcomes from the CoreValve U.S. Pivotal Extreme Risk Study and the real-world NOTION trial (...
The U.S. Food and Drug Administration expanded the approval of a heart valve to include a size small enough to be used in newborn pediatric patients to treat heart defects.
News | Heart Valve Technology | March 07, 2018
The U.S. Food and Drug Administration expanded the approval of a heart valve to include a size small enough to be used...
Videos | Heart Valve Technology | March 02, 2018
Sammy Elmariah, M.D., MPH, interventional structural heart disease, Massachusetts General Hospital, discusses the pro
Overlay Init